Trial · NCT03784495
Melatonin Plus Aminoacids for Sarcopenic Elderly
NCT03784495, Not applicable, Completed, Azienda di Servizi alla Persona di Pavia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Melatonin Plus Aminoacids for Sarcopenic Elderly. Trials, record NCT03784495. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03784495
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Melatonin Plus Aminoacids for Sarcopenic Elderly
- NCT number
- NCT03784495
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 159 participants, actual
- Lead sponsor
- Azienda di Servizi alla Persona di Pavia
- Conditions
- Sarcopenia
- Interventions
- Melatonin 1mg, Essential Aminoacids (eAA), Essential Aminoacids + melatonin, Placebo
- First posted
- 2018-12-24
- Last updated
- 2018-12-24
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Total Fat Mass and Total Free Fat Mass (DXA) | 0, 30 days | Body composition by dual-energy X-ray absorptiometry (DXA). Body composition was measured by DXA, using a Lunar Prodigy DXA (GE Medical Systems, Waukesha, WI). Free Fat mass and Fat mass of specific body regions were measured in kilograms. |
| Primary | Change in Handgrip Strenght | 0, 30 days | Handgrip strength assessed using a Jamar dynamometer adhering to the standardized protocol recommended by the American Society of Hand Therapists. A weak handgrip was defined as \<30 kg for men and \<20 kg for women, based on the average value of the two handgrip measurements of the dominant hand |
| Secondary | Height | At baseline (0) | Height measured in meters |
| Secondary | Change in Body Weight | 0, 30 days | Body Weight measured in kilograms |
| Secondary | Change in serum proteins | 0, 30 days | Serum proteins and albumin were measured by automatic biochemical analyzer. They were reported as g/dl |
| Secondary | Change in blood lipids (total cholesterol and triglycerides) | 0, 30 days | Blood lipids (total cholesterol and triglycerides)were measured by automatic biochemical analyzer. They were reported as mg/dl |
| Secondary | Change in High-sensitivity C-reactive protein (CRP) | 0, 30 days | High-sensitivity C-reactive protein (CRP) was expressed in mg/dl. |
| Secondary | Change in erythrocyte sedimentation rate (ESR) | 0, 30 days | Erythrocyte sedimentation rate (ESR) was expressed in mm/hr. |
| Secondary | Change in glycaemia | 0, 30 days | glycemia was expressed in mg/dl |
| Secondary | Change in Mini Nutritional Assessment (MNA) | 0, 30 days | A mini nutritional assessment (MNA) was performed for all participants. The MNA uses 18 questions regarding simple measurements and a brief questionnaire involving an anthropometric assessment (weight, height and weight loss), a general assessment (lifestyle, medication and mobility), and a dietary assessment (number of meals, food and fluid intake, self-assessment of eating autonomy and self-perception of health and nutrition). Every answer give up to a maximum of 3 points. The sum of all points gives the total MNA. A maximum of 30 points can be achieved. A score of ≥ 24 points describes a well-nourished status. A score of 17 to 23.5 points indicates a risk of malnutrition, while less than 17 points indicates malnutrition. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03784495
GET https://conductscience.org/api/trials/v1/NCT03784495/registered